Table 3.
Studies on colchicine for the prevention of chronic coronary syndromes
| Study | Study design | Dosing | Clinical setting | Patients | Main results |
|---|---|---|---|---|---|
| Nidorf et al.39 (2007) | Prospective study | Colchicine 0.5 mg twice daily for 1 month plus aspirin and high-dose atorvastatin | Stable coronary artery disease patients with elevated hs-CRP | 64 | Reduction of hs-CRP (from 4.58 ± 2.05 mg/L to 1.78 ± 1.38 mg/L, P < 0.01) |
| LoDoCo trial40 (2013) | Randomized trial (observer blinded) | Colchicine 0.5 mg daily for a median of 36 months plus statins and standard secondary prevention drugs | Stable coronary artery disease | 532 | Reduction of cardiovascular events (ACS, out-of-hospital cardiac arrest, non-cardioembolic ischaemic stroke): 5.3% vs. 16% (HR 0.33, 95% CI 0.18–0.59) |
| LoDoCo2 trial21 (2020) | Double-blind RCT | Colchicine 0.5 mg daily vs. placebo | Stable coronary artery disease | 5522 | Reduction of CV death, myocardial infarction, ischaemic stroke, or ischaemia-driven coronary revascularization: 6.8% vs. 9.6% (HR 0.69, 95% CI 0.57–0.83) |
| O’Keefe et al.25w (1992) | Double-blind RCT | Colchicine 0.6 mg twice daily for 6 months | Patients undergoing POBA | 197 | Failure to reduce restenosis (46% vs. 47%, P = NS) |
| Freed et al.26w (1995) | Open-label pilot trial | Colchicine 0.6 mg twice daily for 6 months | Patients undergoing POBA | 50 | Failure to inhibit restenosis (restenosis rate of 53%) |
| Deftereos et al.43 (2013) | Double-blind RCT | Colchicine 0.5 mg twice daily for 6 months | Diabetic patients undergoing PCI with bare-metal stent | 196 | Reduction of in-stent restenosis (16% vs. 33%, P < 0.01) |
| Giannopoulos et al.28w (2015) | Double-blind RCT | Colchicine, 0.5 mg twice daily (half dose if <60 kg), for 10 days | On-pump coronary artery bypass grafting | 59 | Reduction of peak high-sensitivity troponin T concentration within 48 h (616 pg/mL vs. 1613 pg/mL, P < 0.01) and CK-MB concentration (44.6 ng/mL vs. 93 ng/mL, P < 0.01) |
ACS, acute coronary syndrome; CI, confidence interval; CK-MB, creatine kinase-myocardial brain fraction; HR, hazard ratio; hs-CRP, high-sensitivity C-reactive protein; PCI, percutaneous coronary intervention; POBA, plain old balloon angioplasty; RCT, randomized controlled trial.